Skip to main content
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 2004 Nov 15;143(8):1050–1057. doi: 10.1038/sj.bjp.0705944

Identification of R(−)-isomer of efonidipine as a selective blocker of T-type Ca2+ channels

Taiji Furukawa 1,*, Reiko Miura 2, Mitsuyoshi Honda 1, Natsuko Kamiya 1, Yasuo Mori 3, Satoshi Takeshita 1, Takaaki Isshiki 1, Toshihide Nukada 2
PMCID: PMC1575949  PMID: 15545287

Abstract

  1. Efonidipine, a derivative of dihydropyridine Ca2+ antagonist, is known to block both L- and T-type Ca2+ channels. It remains to be clarified, however, whether efonidipine affects other voltage-dependent Ca2+ channel subtypes such as N-, P/Q- and R-types, and whether the optical isomers of efonidipine have different selectivities in blocking these Ca2+ channels, including L- and T-types.

  2. To address these issues, the effects of efonidipine and its R(−)- and S(+)-isomers on these Ca2+ channel subtypes were examined electrophysiologically in the expression systems using Xenopus oocytes and baby hamster kidney cells (BHK tk-ts13).

  3. Efonidipine, a mixture of R(−)- and S(+)-isomers, exerted blocking actions on L- and T-types, but no effects on N-, P/Q- and R-type Ca2+ channels.

  4. The selective blocking actions on L- and T-type channels were reproduced by the S(+)-efonidipine isomer.

  5. By contrast, the R(−)-efonidipine isomer preferentially blocked T-type channels.

  6. The blocking actions of efonidipine and its enantiomers were dependent on holding potentials.

  7. These findings indicate that the R(−)-isomer of efonidipine is a specific blocker of the T-type Ca2+ channel.

Keywords: T-type Ca2+ channel, mammalian cell line, Xenopus oocyte, efonidipine, optical isomer, electrophysiology, selective blocker

Introduction

Efonidipine, a derivative of dihydropyridine (DHP) Ca2+ antagonist, has a unique pharmacological profile, characterized by blockade of both L- and T-type Ca2+ channels (Tanaka & Shigenobu, 2002). The effects of the blockade of T-type Ca2+ channels on the cardiovascular system were studied in the late 1990s using mibefradil, a selective non-DHP blocker of T-type channels (Mishra & Hermsmeyer, 1994). Thereafter, a substantial number of both basic and clinical studies have shown the hemodynamic advantages of blocking T-type channels in the control of hypertension and ischemic heart disease (Hermsmeyer et al., 1997; Van der Vring et al., 1999). Efonidipine is also considered to have a similar favorable hemodynamic effect, based on the blockade of T-type channels. However, the effects of efonidipine on voltage-dependent Ca2+ channels other than L- and T-types have not been studied. Since some DHP Ca2+ antagonists, such as amlodipine, can block N- and P/Q-type Ca2+ channels as well as the L-type (Furukawa et al., 1999), it is essential to determine the selectivity for channel subtypes in understanding the basic and clinical features of the drug.

Furthermore, DHP usually has its optical isomers (enantiomers), and only one of them is capable of blocking L-type channels (Triggle & Rampe, 1989). Therefore, the drug action of any DHP should be specified by its isomers. This is true for efonidipine, which is known to have R(−)- and S(+)-enantiomers (Sakoda et al., 1992). However, the effects of each enantiomer of efonidipine on L- and T-type Ca2+ channels have not yet been characterized.

To address these issues, five different types of voltage-dependent Ca2+ channels (L, N, P/Q, R and T) were functionally expressed in Xenopus oocytes, and the effects of efonidipine on these channels were investigated to clarify the selectivity in channel blockade by efonidipine. For the channels sensitive to efonidipine, the effects of efonidipine were further characterized by R(−)- and S(+)-enantiomers, using both Xenopus oocyte and mammalian cell line expression systems.

Methods

cDNA cloning

Based on the cDNA sequence for the rat α1G subtype (Genbank accession number, AF027984), 14 oligodeoxyribonucleotide primers were synthesized. The sense primers corresponded to the amino-acid residues 1–6 (primer SAG1), 312–319 (SAG2), 638–645 (SAG3), 936–944 (SAG4), 1275–1283 (SAG5), 1643–1651 (SAG6) and 1927–1934 (SAG7): SAG1, CCACATGCTCCC(A/G/C/T)CA(C/T)CG(A/G/C/T)GT; SAG2, GATCCTGCAGGAG(C/T)GT(A/G/C/T)CC(A/G/C/T) AC; SAG3, GCACTAGTGGAGGT(A/G/C/T)GC(A/G/C/T)CC(A/G/C/T)A; SAG4, GAAGAATTTCGACTC(A/G/C/T)CT(A/G/C/T)CT(A/G/C/T)TG; SAG5, GTTTCGTCTCC TGTGTCA(C/T)CG(A/G/C/T)AT; SAG6, CTGAAGATCT G(C/T)AA(C/T)TA(C/T)AT(A/T/C)TT(C/T)AC; and SAG7, GATGGTACCCCA(C/T)CC(A/G/C/T)GA(A/G)GA. The antisense primers corresponded to the amino-acid residues 309–316 (primer AAG1), 633–641 (AAG2), 932–940 (AAG3), 1273–1281 (AAG4), 1640–1647 (AAG5), 1924–1931 (AAG6) and 2281–2286 (AAG7): AAG1, ACTCCTGCAGGA(C/T)C TCAT(A/G/C/T)CC(A/G)TT; AAG2, TCCACTAGTGCTTT(A/G)TC(C/T)TT(A/G/C/T)AG(A/G/T)AT; AAG3, CGAA ATTCTTCCG(A/G)TC(A/G/C/T)GG(C/T)AA(A/G/C/T)GT; AAG4, GACACAGGAGACG(A/G)AA(C/T)CT(A/G/C/T) GA(C/T)TG; AAG5, TGCAGATCTT(A/G/C/T)AG(A/G/C/T)GC(C/T)TC(A/G)TC; AAG6, GGGGTACCAT(A/G/C/T)GT(A/G/C/T)GG(A/G)TG(C/T)TC; and AAG7, ACTCA GGG(A/G)TCCAT(A/G)TC(A/G/C/T)GT(A/G/C/T)GG. Then, seven parts of the rat α1G cDNA were cloned from rat brain poly-(A)+RNA, using a reverse transcription-based polymerase chain reaction (RT–PCR) (Wada et al., 2000) with seven sets of the sense and antisense primers, SAG1/AAG1, SAG2/AAG2, SAG3/AAG3, SAG4/AAG4, SAG5/AAG5, SAG6/AAG6 and SAG7/AAG7. To construct a plasmid containing the entire protein-coding sequences of rat α1G (pBlA1G), each α1G cDNA was excised with EcoRV/Sse8387I, Sse8387I/SpeI, SpeI/ApoI, ApoI/BsmBI, BsmBI/BglII, BglII/KpnI or KpnI/NotI, and recombined into the EcoRV/NotI site of pBluescript SK(+) (Stratagene, CA, U.S.A.). Nucleotide sequence analysis was performed using a DNA sequencer (ABI Prism 377, PE Applied Biosystems, CA, U.S.A.).

The determination of the nucleotide and the predicted amino-acid sequences of the inserts of clone pBlA1G revealed 139 nucleotide changes from the sequence of rat α1G (Perez-Reyes et al., 1998), which resulted in 17 amino-acid substitutions and an insertion of 23 amino acids: His-1060, Cys-1096, Ala-1666, Leu-1699, His-1734, Pro-1811, Ser-1812, Thr-1901, Phe-2148 and Phe-2169 were determined as Leu, Ser, Gly, Ala, Asp, Thr, Leu, Pro, Ser and Ser, encoded by CTA, TCT, GGC, GCT, GAC, ACC, CTC, CCT, TCC and TCC, respectively. The amino-acid residues, EIGKREDASGQLS CIQLPVNSQG (encoded by GAA, ATC, GGC, AAA, CGG, GAA, GAT, GCG, AGT, GGA, CAG, TTA, AGC, TGT, ATT, CAG, CTG, CCT, GTC, AAC, TCT, CAG and GGG), were inserted at the position of 1004. Seven amino-acid residues, SKEKQMA, corresponding to 1580–1586, were substituted by 18 amino-acid residues, NLMLDDVIASGS SASAAS (encoded by AAT, CTA, ATG, TTG, GAC, GAT, GTA, ATT, GCT, TCC, GGC, AGC, TCA, GCC, AGC, GCT, GCG and TCA). In all, 33 nucleotide changes in the sequences were shown not to alter the coding amino-acid residues: C (9), G (15), G (816), T (927), G (951), C (954), C (1059), C (1542), G (1902), T (1908), G (1926), C (1929), A (2802), C (2805), C (2823), C (2829), C (3370), G (3819), G (3825), T (3828), C(3843), G (3846), T (4926), G (4929), C (4938), C (4947), G (5772), C (5778), G (5781), C (5793), C (5796), T (6054) and A (6846) were T, T, A, C, T, A, T, T, C, C, A, G, G, T, G, T, T, A, A, C, T, T, C, C, T, T, A, G, A, T, T, C and G in our clones, respectively. Thus, the insert of this clone contained a cDNA sequence encoding a splice variant of α1G, α1G–bce (Cribbs et al., 2000; Monteil et al., 2000).

In vitro transcription

The 50-bp KpnI/EcoRI fragment was excised from pBluescript SK(+), blunted and inserted into the HindIII (blunted) site of pSPA2 (Nakamura et al., 1994) to produce pSPA3. For in vitro transcription, the 7.0-kb EcoRV/NotI (blunted) fragment containing the entire coding sequence for α1G from pBlA1G was inserted into the EcoRV site of pSPA3 to yield pSPA1G. cRNA specific for the α1G subtype of the T-type Ca2+ channel was synthesized in vitro using a MEGAscript SP6 kit (Ambion, TX, U.S.A.).

Transfection

The 4.0-kb AgeI/BsrGI fragment from pECFP-N1 (Clontech) was blunted with T4 DNA polymerase and circularized with T4 DNA ligase to yield pEnon-N1. In the same orientation with respect to cytomegalovirus gene transcription, the 7.0-kb EcoRV/NotI fragment containing the entire coding sequence for α1G from pBlA1G was ligated with the 4.0-kb SmaI/NotI fragment from pEnon-N1 to yield pEA1G1. Similarly, the 7.0-kb HindIII fragment containing the entire coding sequence for α1C from pSPCDR (Furukawa et al., 1998) was blunted and ligated with the 5.5-kb SmaI fragment from pCI-neo (Promega, WI, U.S.A.) to yield pCIA1C.

Functional expression and electrophysiology

The methods for the in vitro transcription of cRNAs specific for the Ca2+ channel α1, α2/δ and β subunits, and the procedures for the functional expression of Ca2+ channels in Xenopus oocytes have been described previously (Furukawa et al., 1999). Briefly, defolliculated Xenopus oocytes were injected with cRNA specific for Ca2+ channel subunits. cRNAs were used either with 0.3 μg μl−1 of α1G cRNA alone or 0.3 μg μl−1 α1 (α1C (Mikami et al., 1989), α1B (Fujita et al., 1993), α1A (Mori et al., 1991) or α1E (Niidome et al., 1992)) cRNA in combination with 0.2 μg μl−1 α2/δ1 (Mikami et al., 1989) cRNA and 0.1 μg μl−1 β2a (Hullin et al., 1992) cRNA. The oocytes were cultured for 2 to 4 days and then subjected to electrophysiological measurement. The oocytes were positioned in a recording chamber (0.4 ml in volume) perfused with an extracellular solution containing 40 mM Ba(OH)2, 50 mM NaOH, 2 mM KOH and 5 mM HEPES (pH 7.5 with methanesulfonic acid), and Ba2+ currents through expressed channels were measured by the two-microelectrode voltage-clamp method using a GeneClamp 500 amplifier (Axon Instruments, Foster City, CA, U.S.A.). The chamber was perfused continuously (2.0–3.0 ml min−1) with the extracellular solution. Commercial software (pClamp version 6.04, Axon Instruments) was used for generating voltage pulses, acquiring data and analyzing the currents. Oocytes were clamped at a holding potential of −80 mV and depolarized to +10 mV for 200 ms every 15 s, unless otherwise noted. The microelectrodes were filled with 3 M KCl, and those showing a resistance of 0.5–1.2 MΩ were used.

Membrane currents recorded from Xenopus oocytes injected with α1G cRNA were completely blocked by 15 μM mibefradil (n=4), indicating that T-type Ca2+ channels were functionally expressed in Xenopus oocytes, as in the case of L-type (α1Cα2/δ1β2a), N-type (α1Bα2/δ1β2a), P/Q-type (α1Aα2/δ1β2a) and R-type (α1Eα2/δ1β2a) channels (Furukawa et al., 1999).

The baby hamster kidney (BHK) tk-ts13 cell line (Talavera & Basilico, 1977) and its transformant, BHK6, which stably expressed Ca2+ channel α2/δ1 and β1a subunits (Wakamori et al., 1998), were cultured in DMEM medium (Invitrogen, Carlsbad, CA, U.S.A.) containing 5% fetal bovine serum (Invitrogen), 100 U ml−1 penicillin and 100 μg ml−1 streptomycin. For BHK6 cells, the culture medium was further supplemented with 600 μg ml−1 G418 (Sigma, NY, U.S.A.). Cells were cotransfected with the plasmid pEGFP-N1 (Clontech) together either with pEA1G1 or pCIA1C (see above) at a ratio of 1:20 (1 μg in total), using a Lipofectamine reagent (Invitrogen). To express transiently T- and L-type Ca2+ channels, pEA1G1 and pCIA1C were introduced into tk-ts13 and BHK6 cells, respectively. Transfected cells were seeded onto glass coverslips and subjected to electrophysiological measurements after 24–48 h.

The experimental chamber was 0.5 ml in size, and was perfused at a rate of 1 ml/min−1 with a solution containing (in mM) MgCl2 (0.5), BaCl2 (5), CsCl (5.4), tetraethyl-ammonium chloride (TEA-Cl) (132), HEPES (10), 4-aminopyridine (3.0) and glucose (5.5). The solution was titrated to a pH of 7.4 with tetraethyl-ammonium hydroxide. Micropipettes were pulled from 1.5-mm o.d.-walled thin glass tubes (G-1.5, Narishige, Tokyo, Japan) using a horizontal puller (Model P-87, Sutter Instrument Co., Novato, CA, U.S.A.), and were filled with an internal solution having a composition of (in mM): CsCl (150), MgCl2 (3.0), Na2-ATP (5.0), EGTA (5.0) and HEPES (5.0) (pH 7.2 with CsOH). The microelectrodes filled with the internal solution had a tip resistance of 1.5–3 MΩ. An Axopatch 200A amplifier (Axon Instruments, Foster City, CA, U.S.A.) was used for a single-electrode whole-cell voltage clamp (Hamill et al., 1981). Current traces were acquired at 10 kHz and filtered at 2 kHz with an eight-pole low-pass Bessel filter (CyberAmp 320, Axon Instruments). Compensation for series resistance was applied to reduce approximately 75 to 80% of the total resistance. Capacitative and leak currents were eliminated digitally using scaled hyperpolarizing steps of one-fourth amplitude (P/N4). Commercial software (pClamp version 6.04, Axon Instruments) was used for generating voltage pulses, acquiring data and analyzing the currents. All experiments were performed at room temperature (22±1°C). The membrane potential was held at −80 mV, and step depolarization of a 100-ms duration was executed to +10 mV every 10 s.

The drug effects were evaluated after a 5-min perfusion with bath solution containing an agent. In experiments to obtain concentration–blockade relationships, the concentration of DHPs was changed successively. Each experiment was finished within 20 min to avoid a possible run-down of Ba2+ currents. As no detectable current changes were observed during exposure to the vehicle for DHP (0.2% dimethyl sulfoxide (DMSO)), as reported previously (Furukawa et al., 1997), the concentration of DMSO in the bath solution was maintained at 0.2% throughout the experiments. DHPs were dissolved into DMSO just before each experiment and added to the bath solution to make the final concentration. Efonidipine, a racemic mixture of S(+)- and R(−)-enantiomers, and both enantiomers were generous gifts from Nissan Chemical Industries Ltd (Tokyo, Japan). Mibefradil was the generous gift of F. Hoffmann-La Roche, Ltd (Basel, Switzerland). Other drugs were purchased from Sigma (U.S.A.), unless otherwise noted. Concentration-response curves were fitted to the Hill equation: Block (%)=100 (1+(IC50/[D])nH)−1, where IC50 is the concentration at half-blockade, [D] is the drug concentration, and nH is the Hill coefficient.

Data from multiple experiments are expressed by means±s.e.m. Statistical analyses were performed with analysis of variance followed by a Dunett post hoc test. A P-value less than 0.05 was considered significant.

Results

A combination of cRNAs for L-type (α1Cα2/δ1β2a), N-type (α1Bα2/δ1β2a), P/Q-type (α1Aα2/δ1β2a), R-type (α1Eα2/δ1β2a) or T-type (α1G) channels was injected into Xenopus oocytes as described previously (Furukawa et al., 1999). L-, N-, P/Q-, R- and T-type Ca2+ channels were functionally expressed in these oocytes (Figure 1, top, open circles). After a 5-min exposure to 10 μM efonidipine, membrane currents through L- and T-type channels were inhibited to a half-level, as compared with those before application of the drug (Figure 1, top, filled circles; bottom). Efonidipine inhibited N- and P/Q-type channels by less than 10% and failed to block R-type channels.

Figure 1.

Figure 1

Effects of efonidipine on five subtypes of Ca2+ channels (L-, N-, P/Q-, R- and T-types) expressed in Xenopus oocytes. Membrane currents in response to step depolarizations of a 300- or 150-ms duration from a holding potential of −80 to +10 mV (L, N-, P/Q- and R-types), or −20 mV (T-type) before (Control) and after a 5-min perfusion of 10 μM efonidipine are presented with current traces (top). The decrease in the amplitude of the peak inward currents after a 5-min perfusion of 10 μM efonidipine is expressed as a channel blockade in percent (bottom).

To further characterize the blockade of the T-type channel by efonidipine, the channel was expressed in the cell line BHK tk-ts13 (Talavera & Basilico, 1977), as well as in Xenopus oocytes. As shown in Figure 2, the α1G channel blockade by efonidipine was significantly enhanced when the channel was expressed in a BHK cell. The IC50 values for efonidipine block on the T-type channel in both expression systems are summarized in Figure 6 (top). Moreover, the concentration-blockade relationships (Figure 2, bottom) show that the voltage dependences of the channel blockade were also different. Enhancement of the channel blockade by depolarizing the holding potential was obvious at each holding potential (−100, −80 and −60 mV) for BHK cells, while a detectable increase was observed only at −40 mV for oocytes. In order to elucidate the drug effect on channel inactivation, steady-state current availabilities at various membrane potentials were examined in two expression systems. Figure 3 shows the results. Conditioning pulses of 5 s were delivered before the test pulse, and current availability was measured by step depolarization to the membrane potential at which the maximal inward current was observed (usually −20 mV). A similar current inhibition at a very hyperpolarized membrane potential (−120 mV) was observed by 10 μM efonidipine for oocytes (31.5±5.2%, n=8), and by 1 μM efonidipine for BHK cells (30.4±6.8%, n=8). The conditioning pulse voltage at which a half of the channel was inactivated (Vh) was about −60 mV for oocytes, and it was not significantly affected by 10 μM efonidipine. However, the voltage dependence of the channel inactivation was apparently shifted to a hyperpolarizing direction in BHK cells. The Vh was 10 mV negative to that in oocytes, and further shifted −7 mV by exposure to 1 μM efonidipine. Slope factors were not modulated by efonidipine in either system.

Figure 2.

Figure 2

Effects of efonidipine on T-type α1G channels expressed in Xenopus oocytes (a) and BHK cells (b). Membrane currents in response to step depolarizations of a 100-ms duration from a holding potential of −80 to −20 mV before (Control) and after a 5-min perfusion of 1 and 10 μM efonidipine are presented with current traces (top). Concentration–blockade relationships (bottom) for efonidipine at various holding potentials were obtained in oocytes and BHK cells. The block amounts were obtained after a 5-min perfusion of efonidipine. Each data point is an average of more than eight observations.

Figure 6.

Figure 6

The IC50 values for efonidipine and its enantiomers on L- and T-type Ca2+ channels in oocytes (open symbols) and BHK cells (filled symbols) are summarized. The IC50 at each holding potential was estimated from the data in Figures 2 and 5. The values for oocytes are denoted with open symbols, and those for BHK cells with filled symbols. Asterisks denote that the IC50 for BHK cells was significantly smaller than that for oocytes. The Hill's coefficients were the following: enantiomer-unspecified efonidipine in oocytes, 0.8±0.1 at −100 mV, 0.8±0.2 at −80 mV, 0.6±0.2 at −60 mV; S(+)-efonidipine in oocytes, 0.9±0.1 at −100 mV, 0.8±0.2 at −80 mV, 0.7±0.3 at −60 mV; R(−)-efonidipine in oocytes, 0.8±0.1 at −100 mV, 0.8±0.2 at −80 mV, 0.8±0.2 at −60 mV; enantiomer-unspecified efonidipine in BHK cells, 0.7±0.2 at −100 mV, 0.7±0.3 at −80 mV, 0.6±0.2 at −60 mV; S(+)-efonidipine in BHK cells, 0.9±0.2 at −100 mV, 0.7±0.1 at −80 mV, 0.7±0.2 at −60 mV; R(−)-efonidipine in BHK cells, 1.1±0.2 at −100 mV, 0.9±0.3 at −80 mV, 0.9±0.3 at −60 mV. Each data point is an average of more than eight observations. Significant differences in IC50 values at different holding potentials are denoted in the figure.

Figure 3.

Figure 3

Effects of efonidipine on the voltage dependence of α1G channel availability in oocytes and BHK cells. The membrane current amplitudes after a 5-s conditioning pulse to various potentials were measured by test pulse in the control and 5 min after exposure to efonidipine. The concentration of efonidipine was 10 μM for oocytes (a) and 1 μM for BHK cells (b). The membrane voltage of the test pulse was chosen to elicit the maximal inward current (−30 or −20 mV). The raw value of the current amplitude was averaged in Xenopus oocytes (n=8). The current amplitude was normalized to membrane capacitance in BHK cells, and the values (current density) were averaged (n=8). The data was summarized by the following equation:
graphic file with name 143-0705944e1.gif
where Im is membrane current amplitude, Imax is maximal amplitude of current availability, Vc is the voltage of conditioning pulse, Vh is the conditioning pulse voltage at which a half of the channel is inactivated and s is the slope factor of channel inactivation. The values were the following: oocytes in the control, Im=0.46± 0.06 μA, Vh=−56.8±2.8 mV, s=4.8±1.8 mV; oocytes in 10 μM efonidipine, Im=0.31±0.07 μA, Vh=−59.6±5.6 mV, s=5.4±1.6 mV; BHK cells in the control, Im=0.51±0.07 nA/pF, Vh=−67.2± 4.7 mV, s=5.8±2.4 mV; BHK cells in 1 μM efonidpine, Im=0.35±0.06 nA/pF, Vh=−74.9±5.9 mV, s=6.3±1.9 mV.

The effects of the optical isomers of efonidipine on L- and T-type channels were examined in the two expression systems. Figure 4 illustrates the representative current traces showing the effects of the optical isomers, and Figure 5 shows the concentration–blockade relationships for the block of each isomer on two channel subtypes. S(+)-efonidipine inhibited L-type α1Cα2/δ1β2a and T-type α1G channels expressed in Xenopus oocytes (Figure 4a) in a similar concentration-dependent manner (Figure 5a) as that of enantiomer-unspecified efonidipine. The blocking actions of S(+)-efonidipine on the L- and T-type channels were comparable, and the actions were not voltage-dependent in either type of channel, as in the case of enantiomer-unspecified efonidipine. S(+)-efonidipine also inhibited the L- and T-type channels expressed in BHK cells (Figure 4b). The concentration–blockade relationships for both channels were similar, and the blocks were dependent on the holding potential (Figure 5b). The channel sensitivity to S(+)-efonidipine and the voltage dependence were larger in BHK cells compared to those in oocytes. These findings indicate that the S(+)-enantiomer of efonidipine blocked L- and T-type α1G channels as in the case of enantiomer-unspecified efonidipine (Figures 1 and 2), although the channel blockade was more pronounced in BHK cells compared with that in Xenopus oocytes.

Figure 4.

Figure 4

Effects of the optical isomers of efonidipine, S(+)- and R(−)-efonidipine on L- and T-type Ca2+ channels expressed in Xenopus oocytes and BHK cells. (a and b) Membrane currents in response to the step depolarization of a 200- (L-type)- or 100-ms duration (T-type) from a holding potential of −80 to +10 mV before (Control) and after a 5-min perfusion of S(+)- (top) or R(−)-efonidipine (bottom) are presented with current traces. L-type α1Cα2/δβ2a and T-type α1G Ca2+ channels were expressed in Xenopus oocytes (a) or BHK cells (b). In BHK cells, β2a subunit was substituted with β1a subunit. Note that the S(+)-isomer kept the blocking ability of efonidipine for both L- and T-type channels (see Figure 1), but the R(−)-isomer scarcely affected L-type channels.

Figure 5.

Figure 5

Concentration-blockade curves for S(+)- (top) and R(−)-efonidipine (bottom) at three holding potentials (−60, −80 and −100 mV). Blockades of the peak inward currents through T- (left and middle) and L-type channels (right) expressed in Xenopus oocytes (a) and BHK cells (b) were measured after a 5-min perfusion of various concentrations of the isomers.

On the other hand, R(−)-efonidipine inhibited T-type α1G channels expressed in both Xenopus oocytes (Figure 4a, bottom) and BHK cells (Figure 4b, bottom). In contrast to the effect by S(+)-efonidipine, R(−)-efonidipine failed to inhibit L-type α1C channels, regardless of whether they were expressed in Xenopus oocytes or BHK cells (Figure 4, bottom). The R(−)-efonidipine block on the T-type channel was steeply voltage-dependent in BHK cells. The blockade of membrane current by 0.1 μM R(−)-efonidipine was increased four-fold by depolarizing the holding potential from −100 to −60 mV. The increase was 2.8-fold in the case of S(+)-efonidipine.

Figure 6 summarizes the IC50's for the blockade of the L- and T-type Ca2+ channels by efonidipine, S(+)-efonidipine and R(−)-efonidipine. In each combination of drug and channel, the IC50 for channel in BHK cells was smaller than that in Xenopus oocytes. This was true at each holding potential. R(−)-efonidipine blocked T-type channels in Xenopus oocytes slightly more potently than S(+)-enantiomer, and the IC50 was not changed by holding potentials in the range of −100 to −60 mV. Both S(+)- and R(−)-efonidipine enantiomers blocked T-type α1G channels in BHK cells with comparable IC50 values. However, the voltage dependence of channel blockade was steeper in R(−)-efonidipine than in S(+)-efonidipine. The Hill coefficients were not markedly influenced by the enantiomers or the expression systems. These findings taken together indicate that R(−)-efonidipine, but not S(+)-efonidipine, is a selective blocker of the T-type Ca2+ channel.

Discussion

In the present study, the high-voltage-activated L- (α1C), N- (α1B), P/Q- (α1A) and R-type (α1E) Ca2+ channels and the low-voltage-activated T-type (α1G) Ca2+ channel were functionally expressed in the expression systems using Xenopus oocytes and cultured BHK cells. The high-voltage-activated channels were expressed with auxiliary α2/δ and β subunits and the α1G channel was expressed as a single molecule, as the forms that are known to work as the channels found in native tissues (Perez-Reyes, 2003b). We found that efonidipine blocked L- and T-type Ca2+ channel activities and failed to influence N-, P/Q- and R-type Ca2+ channels. Of the two optical isomers of efonidipine, only S(+)-isomer blocked both T- and L-type channels, indicating that the selectivity of efonidipine for channel blockade is derived from the S(+)-isomer of efonidipine. By contrast, the other isomer of efonidipine, R(−)-isomer, blocked T-type channels without affecting the L-type. These results provide evidence that the R(−)-isomer of efonidipine is a T-type-specific blocker.

The efonidipine employed in this study is commercially available as a DHP L-type Ca2+ channel antagonist with less marked reflex sympathomimetic actions (Masuda & Tanaka, 1994). In addition, efonidipine has been shown to inhibit myocardial T-type Ca2+ channels (Masumiya et al., 1997; 1998) and the molecularly identified α1H subtype of T-type Ca2+ channels (Ono et al., 2000). Therefore, efonidipine is classified into the category of dual blocker of T- and L-type Ca2+ channels (Tanaka & Shigenobu, 2002). It is also known that some DHP derivatives block N- and P/Q-type channels as well as L-type channels (Uneyama et al., 1997; Furukawa et al., 1999). However, in the present study, efonidipine and its S(+)-isomer blocked only L-type channels among all the high-voltage-activated Ca2+ channels examined.

Generally, DHP acts on L-type Ca2+ channels as a blocker or a stimulator. For example, one of the two optical isomers of Bay K-8644 stimulates the L-type channel, whereas the other blocks it (Triggle & Rampe, 1989). With respect to the L-type Ca2+ channel, the S(+)-enantiomer, but not the R(−)-enantiomer, of efonidipine blocked L-type α1C channels, which is consistent with a previous report (Sakoda et al., 1992). With respect to the T-type Ca2+ channel, efonidipine blocked T-type α1G channels as reported regarding T-type α1H Ca2+ channels (Ono et al., 2000), and unlike the L-type, the channel blockades were not optical isomer-specific.

The transmembrane segments S5 and S6 of repeat III and the transmembrane segment S6 of repeat IV have been assigned to the interaction sites of L-type Ca2+ channels with DHP (Hockerman et al., 1997; Hering et al., 1998; Striessnig et al., 1998). In these regions of Ca2+ channels, amino-acid sequences of T-type α1G, α1H and α1I channels are the most diverse compared to those of L-type α1C, α1S and α1D channels among the voltage-dependent Ca2+ channels known (Perez-Reyes, 2003a). These findings suggest that efonidipine interacts with L- and T-type Ca2+ channels in a different mode or through different sites.

In this study, two different heterologous expression systems were used for L-type α1Cα2/δβ channels and T-type α1G channels. The steady-state current availability curve (Figure 3) showed that the voltage dependence of inactivation in BHK cells was shifted about 10 mV for the hyperpolarizing direction compared to that in oocytes. As shown in Figure 2, the time course of membrane current inactivation at −20 mV seemed faster in BHK cells. Although the cause of the shift was not clarified, the differences in recording methods, that is, double microelectrodes vs whole cell patch, and 5 vs 40 mM external Ba2+, partially contributed to the different voltage dependence of channel inactivation. Such altered voltage dependences of the α1G channel in different expression and recording systems have been seen in previous reports (Perez-Reyes et al., 1998; Lee et al., 1999; Cribbs et al., 2000; Marksteiner et al., 2001).

Changing the expression system from that of oocytes to that of BHK cells apparently increased the channel sensitivity to efonidipine in both L- and T-type channels. The estimated IC50 for block on T-type channels by enantiomer-unspecified efonidipine at −100 mV was 10.8-fold larger in oocytes than that in BHK cells. A similar difference (10.3-fold) was observed for L-type channels as well. Moreover, the voltage dependence of blockades was also different between the two systems. As in Figure 6, the IC50 for the R(−)-enantiomer in BHK cells was decreased 60-fold by depolarizing the holding potential from −100 to −60 mV, while the value was not significantly changed in oocytes. A similar distinct voltage dependence of block was observed for the effect of enantiomer-unspecified efonidipine and the S(+)-enantiomer. Explanations for the different effects have not been fully provided at this point. Altered voltage dependence may partially contribute to the different effects of efonidipine and its isomers. However, the results in Figure 3 could not be explained by the different voltage dependence of inactivation, in which 1 μM efonidipine in BHK cells and 10 μM efonidipine in oocytes showed a similar block at a very hyperpolarized membrane potential (−120 mM). These discrepancies may arise due to different lipid compositions of the cell membrane between Xenopus oocytes and BHK cells, which influence activities of Ca2+ channels (Cannon et al., 2003) and Ca2+ channel antagonists (Mason, 1993). Further evaluations are necessary to fully elucidate the different efonidipine action in two systems. Nevertheless, the relative selectivity of efonidipine and its enantiomers for L- and T-type channel subtypes were similar in the two expression systems. In both expression systems, the IC50 for R(−)-efonidipine block of L-type channels was more than 100-fold larger than that of T-type channels at a holding potential of −100 mV. Therefore, the L- and T-type selective effect of efonidipine on the series of Ca2+ channel subtypes shown in Figure 1 is considered to be independent of the expression system used.

Studies with mibefradil, a non-DHP blocker specific for T-type Ca2+ channels, have implied that selective inhibition of T-type Ca2+ channels is advantageous in the treatment of hypertension or angina pectoris (Hermsmeyer et al., 1997; Van der Vring et al., 1999). However, mibefradil was withdrawn from the market because of serious pharmacokinetic and pharmacodynamic interactions with other drugs frequently administered to patients with cardiovascular diseases (Krayenbuhl et al., 1999). Therefore, the development of a new T-type Ca2+ channel blocker without adverse effects has been considered necessary for medication. Efonidipine has been clinically evaluated as an agent which shows cardiac (Harada et al., 2003) and renal protective functions (Hayashi et al., 2003). These clinical effects of efonidipine are consistent with the high expression of α1G mRNA in the cardiac muscle and kidneys after hypertrophy or myocardial infarction (Sen & Smith, 1994; Martinez et al., 1999; Andreasen et al., 2000) and our finding that efonidipine blocked the α1G channel. Therefore, the clinical use of the R(−)-isomer of efonidipine, which specifically blocks T-type Ca2+ channels, is perhaps the most intriguing.

In conclusion, the characterization of agents for their specificity to each channel subtype, as we did in this study, should be essential for clarifying the relationship between the three-dimensional structure of Ca2+ channel antagonists and their specific actions on Ca2+ channel subtypes, to develop more effective and safer drugs.

Acknowledgments

We are grateful to Drs Atsushi Mikami and Tsutomu Tanabe for providing us with α1C and α2/δ1 cDNAs, and Dr Yoshihiko Fujita for his generous gift of α1B cDNA. We also thank Drs Toru Yamashita, Yukinori Masuda and Mitsunobu Yoshii for the critical reading of the manuscript. This investigation was supported in part by research grants from the Ministry of Education, Science and Culture of Japan to T.F. (#14570698) and to T.N. (#12680766 and #14580758).

Abbreviations

DHP

dihydropyridine

DMSO

dimethyl sulfoxide

References

  1. ANDREASEN D., JENSEN B.L., HANSEN P.B., KWON T.H., NIELSEN S., SKOTT O. The alpha(1G)-subunit of a voltage-dependent Ca(2+) channel is localized in rat distal nephron and collecting duct. Am. J. Physiol. Renal Physiol. 2000;279:F997–1005. doi: 10.1152/ajprenal.2000.279.6.F997. [DOI] [PubMed] [Google Scholar]
  2. CANNON B., HERMANSSON M., GYORKE S., SOMERHARJU P., VIRTANEN J.A., CHENG K.H. Regulation of calcium channel activity by lipid domain formation in planar lipid bilayers. Biophys. J. 2003;85:933–942. doi: 10.1016/S0006-3495(03)74532-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. CRIBBS L.L., GOMORA J.C., DAUD A.N., LEE J.H., PEREZ-REYES E. Molecular cloning and functional expression of Ca(v)3.1c, a T-type calcium channel from human brain. FEBS Lett. 2000;466:54–58. doi: 10.1016/s0014-5793(99)01756-1. [DOI] [PubMed] [Google Scholar]
  4. FUJITA Y., MYNLIEFF M., DIRKSEN R.T., KIM M.-S., NIIDOME T., NAKAI J., FRIEDRICH T., IWABE N., MIYATA T., FURUICHI T., FURUTAMA D., MIKOSHIBA K., MORI Y., BEAM K.G. Primary structure and functional expression of the Ω-conotoxin-sensitive N-type calcium channel from rabbit brain. Neuron. 1993;10:585–598. doi: 10.1016/0896-6273(93)90162-k. [DOI] [PubMed] [Google Scholar]
  5. FURUKAWA T., MIURA R., MORI Y., STROBECK M., SUZUKI K., OGIHARA Y., ASANO T., MORISHITA R., HASHII M., HIGASHIDA H., YOSHII M., NUKADA T. Differential interactions of the C treminus and the cytoplasmic I-II loop of neuronal Ca2+ channels with G-protein a and bg subunits II. evidence for direct binding. J. Biol. Chem. 1998;273:17595–17603. doi: 10.1074/jbc.273.28.17595. [DOI] [PubMed] [Google Scholar]
  6. FURUKAWA T., NUKADA T., SUZUKI K., FUJITA Y., MORI Y., NISHIMURA M., YAMANAKA M. Voltage and pH dependent block of cloned N-type Ca2+ channels by amlodipine. Br. J. Phamacol. 1997;121:1136–1140. doi: 10.1038/sj.bjp.0701226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. FURUKAWA T., YAMAKAWA T., MIDERA T., SAGAWA T., MORI Y., NUKADA T. Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 1999;291:464–473. [PubMed] [Google Scholar]
  8. HAMILL O.P., MARTY E., NEHER B., SAKMANN B., SIGWORTH F.J. Improved patch-clamp techniques for high- resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 1981;391:85–100. doi: 10.1007/BF00656997. [DOI] [PubMed] [Google Scholar]
  9. HARADA K., NOMURA M., NISHIKADO A., UEHARA K., NAKAYA Y., ITO S. Clinical efficacy of efonidipine hydrochloride, a T-type calcium channel inhibitor, on sympathetic activities. Circ. J. 2003;67:139–145. doi: 10.1253/circj.67.139. [DOI] [PubMed] [Google Scholar]
  10. HAYASHI K., OZAWA Y., FUJIWARA K., WAKINO S., KUMAGAI H., SARUTA T. Role of actions of calcium antagonists on efferent arterioles – with special references to glomerular hypertension. Am. J. Nephrol. 2003;23:229–244. doi: 10.1159/000072054. [DOI] [PubMed] [Google Scholar]
  11. HERING S., BERJUKOW S., ACZÉL S., TIMIN E.N. Ca2+ channel block and inactivation: common molecular determinants. Trends Pharmacol. Sci. 1998;19:439–443. doi: 10.1016/s0165-6147(98)01258-9. [DOI] [PubMed] [Google Scholar]
  12. HERMSMEYER K., MISHRA S., MIYAGAWA K., MINSHALL R. Physiologic and pathophysiologic relevance of T-type calcium-ion channels: potential indications for T-type calcium antagonists. Clin. Ther. 1997;19 Suppl A:18–26. doi: 10.1016/s0149-2918(97)80034-3. [DOI] [PubMed] [Google Scholar]
  13. HOCKERMAN G.H., PETERSON B.Z., JOHNSON B.D., CATTERALL W.A. Molecular determinants of drug binding and action on L-type calcium channels. Annu. Rev. Pharmacol. Toxicol. 1997;37:361–396. doi: 10.1146/annurev.pharmtox.37.1.361. [DOI] [PubMed] [Google Scholar]
  14. HULLIN R., SINGER-LAHAT D., FREICHEL M., BIEL M., DASCAL N., HOFMANN F., FLOCKERZI V. Calcium channel beta subunit heterogeneity: functional expression of cloned cDNA from heart, aorta and brain. EMBO J. 1992;11:885–890. doi: 10.1002/j.1460-2075.1992.tb05126.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. KRAYENBUHL J.C., VOZEH S., KONDO-OESTREICHER M., DAYER P. Drug–drug interactions of new active substances: mibefradil example. Eur. J. Clin. Pharmacol. 1999;55:559–565. doi: 10.1007/s002280050673. [DOI] [PubMed] [Google Scholar]
  16. LEE J.H., DAUD A.N., CRIBBS L.L., LACERDA A.E., PEREVERZEV A., KLOCKNER U., SCHNEIDER T., PEREZ-REYES E. Cloning and expression of a novel member of the low voltage-activated T-type calcium channel family. J. Neurosci. 1999;19:1912–1921. doi: 10.1523/JNEUROSCI.19-06-01912.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. MARKSTEINER R., SCHURR P., BERJUKOW S., MARGREITER E., PEREZ-REYES E., HERING S. Inactivation determinants in segment IIIS6 of Ca(v)3.1. J. Physiol. 2001;537:27–34. doi: 10.1111/j.1469-7793.2001.0027k.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. MARTINEZ M.L., HEREDIA M.P., DELGADO C. Expression of T-type Ca(2+) channels in ventricular cells from hypertrophied rat hearts. J. Mol. Cell Cardiol. 1999;31:1617–1625. doi: 10.1006/jmcc.1999.0998. [DOI] [PubMed] [Google Scholar]
  19. MASON R.P. Membrane interaction of calcium channel antagonists modulated by cholesterol. Implications for drug activity. Biochemi. Pharmacol. 1993;45:2173–2183. doi: 10.1016/0006-2952(93)90186-z. [DOI] [PubMed] [Google Scholar]
  20. MASUDA Y., TANAKA S. Efonidipine hydrochloride: a new calcium antagonist. Cardivasc. Drug Rev. 1994;12:123–135. [Google Scholar]
  21. MASUMIYA H., SHIJUKU T., TANAKA H., SHIGENOBU K. Inhibition of myocardial L- and T-type Ca2+ currents by efonidipine: possible mechanism for its chronotropic effect. Eur. J. Pharmacol. 1998;349:351–357. doi: 10.1016/s0014-2999(98)00204-0. [DOI] [PubMed] [Google Scholar]
  22. MASUMIYA H., TANAKA H., SHIGENOBU K. Effects of Ca2+ channel antagonists on sinus node: prolongation of late phase 4 depolarization by efonidipine. Eur. J. Pharmacol. 1997;335:15–21. doi: 10.1016/s0014-2999(97)01150-3. [DOI] [PubMed] [Google Scholar]
  23. MIKAMI A., IMOTO K., TANABE T., NIIDOME T., MORI Y., TAKESHIMA H., NARUMIYA S., NUMA S. Primary structure and functional expression of the cardiac dihydropyridine-sensitive calcium channel. Nature. 1989;340:230–233. doi: 10.1038/340230a0. [DOI] [PubMed] [Google Scholar]
  24. MISHRA S.K., HERMSMEYER K. Selective inhibition of T-type Ca2+ channels by Ro 40-5967. Circ. Res. 1994;75:144–148. doi: 10.1161/01.res.75.1.144. [DOI] [PubMed] [Google Scholar]
  25. MONTEIL A., CHEMIN J., BOURINET E., MENNESSIER G., LORY P., NARGEOT J. Molecular and functional properties of the human alpha(1G) subunit that forms T-type calcium channels. J. Biol. Chem. 2000;275:6090–6100. doi: 10.1074/jbc.275.9.6090. [DOI] [PubMed] [Google Scholar]
  26. MORI Y., FRIEDRICH T., KIM M.-S., MIKAMI A., NAKAI J., RUTH P., BOSSE E., HOFMANN F., FLOCKERZI V., FURUICHI T., MIKOSHIBA K., IMOTO K., TANABE T., NUMA S. Primary structure and functional expression from complementary DNA of a brain calcium channel. Nature. 1991;350:398–402. doi: 10.1038/350398a0. [DOI] [PubMed] [Google Scholar]
  27. NAKAMURA K., NUKADA T., HAGA T., SUGIYAMA H. G protein-mediated inhibition of phosphoinositide metabolism evoked by metabotropic glutamate receptors in frog oocytes. J. Physiol. 1994;474:35–41. doi: 10.1113/jphysiol.1994.sp020000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. NIIDOME T., KIM M.S., FRIEDRICH T., MORI Y. Molecular cloning and characterization of a novel calcium channel from rabbit brain. FEBS Lett. 1992;308:7–13. doi: 10.1016/0014-5793(92)81038-n. [DOI] [PubMed] [Google Scholar]
  29. ONO K., LEE T.-S., KAKU T., ARITA M. Pharmacological properties of the human cardiac cloned T-type calcium channel. Jpn. J. Electrocardiol. 2000;20:109–112. [Google Scholar]
  30. PEREZ-REYES E. Molecular physiology of low-voltage-activated t-type calcium channels. Physiol. Rev. 2003a;83:117–161. doi: 10.1152/physrev.00018.2002. [DOI] [PubMed] [Google Scholar]
  31. PEREZ-REYES E. Molecular physiology of low-voltage-activated t-type calcium channels. Physiol. Rev. 2003b;83:117–161. doi: 10.1152/physrev.00018.2002. [DOI] [PubMed] [Google Scholar]
  32. PEREZ-REYES E., CRIBBS L.L., DAUD A., LACERDA A.E., BARCLAY J., WILLIAMSON M.P., FOX M., REES M., LEE J.H. Molecular characterization of a neuronal low-voltage-activated T-type calcium channel. Nature. 1998;391:896–900. doi: 10.1038/36110. [DOI] [PubMed] [Google Scholar]
  33. SAKODA R., MATSUMOTO H., SETO K. Synthesis and crystal structure of optically active 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dim ethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate (NZ-105) Chem. Pharm. Bull. (Tokyo) 1992;40:2377–2381. doi: 10.1248/cpb.40.2377. [DOI] [PubMed] [Google Scholar]
  34. SEN L., SMITH T.W. T-type Ca2+ channels are abnormal in genetically determined cardiomyopathic hamster hearts. Circ. Res. 1994;75:149–155. doi: 10.1161/01.res.75.1.149. [DOI] [PubMed] [Google Scholar]
  35. STRIESSNIG J., GRABNER M., MITTERDORFER J., HERING S., SINNEGGER M.J., GLOSSMANN H. Structural basis of drug binding to L Ca2+ channels. Trends Pharmacol. Sci. 1998;19:108–115. doi: 10.1016/s0165-6147(98)01171-7. [DOI] [PubMed] [Google Scholar]
  36. TALAVERA A., BASILICO C. Temperature sensitive mutants of BHK cells affected in cell cycle progression. J. Cell. Physiol. 1977;92:425–436. doi: 10.1002/jcp.1040920310. [DOI] [PubMed] [Google Scholar]
  37. TANAKA H., SHIGENOBU K. Efonidipine hydrochloride: a dual blocker of L- and T-type ca(2+) channels. Cardiovasc. Drug Rev. 2002;20:81–92. doi: 10.1111/j.1527-3466.2002.tb00084.x. [DOI] [PubMed] [Google Scholar]
  38. TRIGGLE D.J., RAMPE D. 1,4-Dihydropyridine activators and antagonists: structural and functional distinctions. Trends Pharmacol. Sci. 1989;10:507–511. doi: 10.1016/0165-6147(89)90051-5. [DOI] [PubMed] [Google Scholar]
  39. UNEYAMA H., TAKAHARA A., DOHMOTO H., YOSHIMOTO R., INOUE K., AKAIKE N. Blockade of N-type Ca2+ current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurones. Br. J. Pharmacol. 1997;122:37–42. doi: 10.1038/sj.bjp.0701342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. VAN DER VRING J.A., CLEOPHAS T.J., VAN DER WALL E.E., NIEMEYER M.G. T-channel-selective calcium channel blockade: a promising therapeutic possibility, only preliminarily tested so far: a review of published data. T-Channel Calcium Channel Blocker Study Group. Am. J. Ther. 1999;6:229–233. [PubMed] [Google Scholar]
  41. WADA Y., YAMASHITA T., IMAI K., MIURA R., TAKAO K., NISHI M., TAKESHIMA H., ASANO T., MORISHITA R., NISHIZAWA K., KOKUBUN S., NUKADA T. A region of the sulfonylurea receptor critical for a modulation of ATP-sensitive K+ channels by G-protein bg-subunits. EMBO J. 2000;19:4915–4925. doi: 10.1093/emboj/19.18.4915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. WAKAMORI M., YAMAZAKI K., MATSUNODAIRA H., TERAMOTO T., TANAKA I., NIIDOME T., SAWADA K., NISHIZAWA Y., SEKIGUCHI N., MORI E., MORI Y., IMOTO K. Single tottering mutations responsible for the neuropathic phenotype of the P-type calcium channel. J. Biol. Chem. 1998;273:34857–34867. doi: 10.1074/jbc.273.52.34857. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES